2007-12-24 01:37:02 Xinhua English
BEIJING, Dec. 24 (Xinhua) -- China announced here Monday that its human-use bird flu vaccine proves "safe" and "effective" during the second phase of clinical tests.
The vaccine was jointly developed by the Beijing-based vaccine producer Sinovac Biotech, the first in the world to develop SARS vaccine, and the Chinese Center for Disease Control and Prevention. The program was also under support of the Ministry of Science and Technology and the Ministry of Health.
Zhang Jiansan, vice general manager of the Sinovac Biotech, said the second phase of clinical tests was carried out from September to November with approval of the Chinese State Food and Drug Administration. A total of 402 people aged from 18 to 60 took the test.
Test results showed that the major index of the vaccine all reached international standard and performed well in human body. None of the test takers were found with serious negative reaction, which proved that the vaccine was safe.
Zhang said test takers of different ages were given different dosage of vaccine, and the result was also positive. "It means the vaccine could give multiple choices in treating flu infected people."
"We were able to control the dosage and immunization procedure during the second phase of clinical tests, which also provided us scientific and effective methods to combat highly infective influenza," Zhang said.
Observers said China has completed its technological preparation to combat influenza with the success of human-use birdflu vaccine research and clinical tests.
"China is also capable to produce human-use bird flu vaccine inappropriate quantity," Zhang stressed.